All Posts: clinical trials
-
Investigational Drug Shows Promise in a Clinical Trial for Lung Cancers With ALK Mutations
Early signals from phase 1 of the ALKOVE-1 clinical trial suggest potential benefit from the use of an investigational drug called NVL-655 in people whose non-small cell lung cancer has alterations in a gene called ALK.
Category: News Release
-
ISPY2: A Unique, Flexible Breast Cancer Trial for Modern Times
The ISPY2 breast cancer clinical trial is a unique phase 2 study that offers a broad range of treatment options for patients with locally advanced breast cancer.
Category: Lombardi Stories
-
Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
Category: News Release
-
The Aspirin Conundrum: Navigating Negative Results, Age, Aging Dynamics and Equity
A new study examining the role of aspirin in breast cancer treatment reveals critical issues related to health equity and aging that have broad implications for cancer and other disease intervention trials, say researchers from Georgetown University’s Lombardi Comprehensive Cancer Center. They outline their concerns in an editorial accompanying the study’s findings published April 29 in the JAMA.
Category: News Release
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: Lombardi Stories
-
The Winn Awards is looking for the next cohort of Cancer Development Award scholars
Applications accepted through May 13 through the Robert A. Winn Diversity in Clinical Trials Award Program (Winn Awards), which seeks to increase diversity in clinical trials and transform the clinical research landscape.
Category: DEI Funding Opportunities
-
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer Uncovered
How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: News Release
-
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown University’s Lombardi Comprehensive Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma.
Category: Lombardi Stories
-
Ruesch Symposium Participants Encourage Patients to Consider Clinical Trials
(December 2, 2022) — After being diagnosed with pancreatic cancer in April 2021, Jan Baird-Adams, a librarian from Maryland, had lots of questions for her oncologist, Marcus Noel, MD, associate professor of oncology and director of the Clinical Research Management Office at Georgetown Lombardi Comprehensive Cancer Center. “Dr. Noel and his staff were incredibly kind […]
Category: Lombardi Stories